24 papers · ranked by Valyu relevance
Xin Lin, Kuan Kang, Pan Chen, Zhaoyang Zeng + 4 more
Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules.…
Jiabei He, Ying Hu, Mingming Hu, Baolan Li
Lung cancer is currently the leading cause of cancer-related death in worldwide, non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum-based chemotherapy, molecular targeted agents and radiotherapy are the main treatment of NSCLC. With the strategies of treatment constantly…
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao + 2 more
'Zhen Zhang'] Programmed death protein 1 (PD1) is a common immunosuppressive member on the surface of T cells and plays an imperative part in downregulating the immune system and advancing self-tolerance. Its ligand programmed cell death ligand 1 (PDL1) is overexpressed on the surface of malignant tumor cells, where it…
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok
Targeting PD-L1 and PD-1 interactions is a relatively new therapeutic strategy used to treat cancer. Inhibitors of PD-1/PD-L1 include peptides, small molecule chemical compounds, and antibodies. Several approved antibodies targeting PD-1 or PD-L1 have been patented with good curative effect in various cancer types in…
Yating Zhao, Liu Liu, Liang Weng
Over the past decade, diverse PD-1/PD-L1 blockades have demonstrated significant clinical benefit in across a wide range of tumor and cancer types. With the increasing number of PD-1/PD-L1 blockades available in the market, differences between the clinical performance of each of them started to be reported. Here, we…
Prageeth R. Wijewardhane, Krupal P. Jethava, Jonathan A Fine, Gaurav Chopra
The Programmable Cell Death Protein 1/Programmable Death-Ligand 1 (PD-1/PD-L1) interaction is an immune checkpoint utilized by cancer cells to enhance immune suppression. There exists a huge need to develop small molecules drugs that are fast acting, cheap, and readily bioavailable compared to antibodies.…
Komang Alit Paramitasari, Yasumasa Ishida
To investigate the effect of a major histocompatibility complex class I (MHC-I) overexpression to augment immune sensitivity against tumors, we have generated the murine colorectal carcinoma cell line MC38 (with the endogenous H-2^b^ haplotype) overexpressing the allogeneic mouse MHC-I cell surface molecule H-2K^d^…
Hongmei Zheng, Yue Ning, Yuting Zhan, Sile Liu + 2 more
'Songqing Fan'] PD-1 (Programmed cell death protein-1) is mainly expressed in various immune cells, while its ligands PD-L1/PD-L2 (Programmed death ligand-1/Programmed death ligand-2) are mostly expressed in tumor cells. Generally, the binding of PD-L1/PD-L2 and PD-1 could lead to the tumor immune evasion. However…
Margherita Passariello, Anna Morena D’Alise, Annachiara Esposito, Cinzia Vetrei + 4 more
'Cinzia Vetrei' 'Guendalina Froechlich' 'Elisa Scarselli' 'Alfredo Nicosia' 'Claudia De Lorenzo'] The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Maya Gershkovitz, Olga Yajuk, Tanya Fainsod-Levi, Zvi Granot
The PD-L1/PD-1 axis was shown to promote tumor growth and progression via the inhibition of anti-tumor immunity. Blocking this axis was shown to be beneficial in maintaining the anti-tumor functions of the adaptive immune system. Still, the consequences of blocking the PD-L1/PD-1 axis on innate immune responses remain…
Xiaoyan Liu, Linglu Wang, Yuhang Han, Hsiang-i Tsai + 6 more
Immunotherapy represented by the programmed death-1 (PD-1)/ligand 1 (PD-L1) monoclonal antibodies has led tumor treatment into a new era. However, the low overall response rate and high incidence of drug resistance largely damage the clinical benefits of existing immune checkpoint therapies. Recent studies correlate…
Renpeng Ding, Shang Liu, Shanshan Wang, Huanyi Chen + 7 more
PD-L1 expression levels in tumors do not consistently predict cancer patients’ response to PD-(L)1 inhibitors. We therefore evaluated how tumor PD-L1 levels affect the anti-PD-(L)1 efficacy and T cell function. We used MART-1-specific TCR-T cells (TCR-T_MART-1_) stimulated with MART-1_27-35_ peptide-loaded MEL-526…
Kamran Kaveh, Feng Fu
Immune checkpoint therapy is one of the most promising immunotherapeutic methods that are likely able to give rise to durable treatment response for various cancer types. Despite much progress in the past decade, there are still critical open questions with particular regards to quantifying and predicting the efficacy…
K Hudson, NA Cross, N Jordan-Mahy, R Leyland
Programmed death-ligand 1 (PD-L1) expression is a survival mechanism employed by tumours to mediate immune evasion and tumour progression. PD-1/PD-L1-targeted therapies have revolutionised the cancer therapy landscape due to their ability to promote durable anti-tumour immune responses in select patients with advanced…
Authors not listed
免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）已成功应用于多种恶性肿瘤治疗，其中程序化细胞死亡蛋白（programmed death 1, PD-1）/程序化细胞死亡配体-1（programmed death ligand 1, PD-L1）抑制剂近年来开始用于非小细胞肺癌中。目前认为PD-1/PD-L1抑制剂具有较小的副作用，并不会增加感染风险。但目前出现了免疫治疗相关不良事件（immune-related adverse events…
Shuang Qu, Zichen Jiao, Geng Lu, Bing Yao + 13 more
Although blockade of programmed death-ligand 1 (PD-L1) to enhance T cell immune responses shows great promise in tumor immunotherapy, the efficacy of such immune-checkpoint inhibition strategy is limited for patients with solid tumors. The mechanism underlying the limited efficacy of PD-L1 inhibitors remains unclear.…
Chenghang Li, Haifeng Zhang, Xiulan Lai, Jinzhi Lei
The tumor-immune system plays a critical role in colorectal cancer progression. Recent preclinical and clinical studies showed that combination therapy with anti-PD-L1 and cancer vaccines improved treatment response. In this study, we developed a multiscale mathematical model of interactions among tumors, immune cells…
Serap Gokcen, Tianyuan Chu, Phoebe Blair, Natalia Krajewska + 4 more
Immune checkpoint therapies aim to restore anti-tumour immunity by blocking inhibitory signals that suppress T-cell activation. The most effective current strategies use humanised antibodies targeting PD1 or its ligand PDL1. However, due to their large size, antibodies often exhibit limited tissue diffusion, resulting…
Weizhi Wang, Limin Zhang
Blocking programmed cell death ligand 1 (PD-L1) in tumor cells is an effective therapy strategy to achieve immune system activation for tumor therapy, however only a few patients can benefit from it. Development of synergistic therapy with checkpoint PD-L1 blockade immunotherapy is beneficial to enhance antitumor…
Yetkin Ağaçkıran, Funda Aksu, Nalan Akyürek, Caner Ercan + 2 more
'Şevki Mustafa Demiröz' 'Kurtuluş Aksu'] Results: PD-L1 antibody positivity is encountered in 72.3% of surgically resected sarcomatoid lung carcinomas. Regarding histopathologic subtypes PD-L1 expression was positive in 80.4% of pleomorphic carcinomas, 62.5 % of spindle and/or giant cell carcinomas and 16.7% of…
Ansh Kapil, Armin Meier, Aleksandra Żuraw, Keith E. Steele + 3 more
'Marlon C. Rebelatto' 'Günter Schmidt' 'Nicolas Brieu'] The level of PD-L1 expression in immunohistochemistry (IHC) assays is a key biomarker for the identification of Non-Small-Cell-Lung-Cancer (NSCLC) patients that may respond to anti PD-1/PD-L1 treatments. The quantification of PD-L1 expression currently includes…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Ansh Kapil, Tobias Wiestler, Simon Lanzmich, Abraham Silva + 4 more
'Keith E. Steele' 'Marlon C. Rebelatto' 'Guenter Schmidt' 'Nicolas Brieu'] Abstract. The analysis of the tumor environment on digital histopathology slides is becoming key for the understanding of the immune response against cancer, supporting the development of novel immuno-therapies. We introduce here a novel deep…